Navigation Links
Novel therapy combinations gain ground in treating hepatitis

ies which will evaluate the ability of VX-950 to produce sustained viral responses with as little as 12 weeks of therapy." VX-950 + pegIFN + RBV was well tolerated, with no serious adverse events and no treatment discontinuations. A detailed analysis of adverse events will be presented.

Acetaminophen as a co-factor in acute liver failure due to viral hepatitis determined by measurement of acetaminophen-protein adducts [Abstract S1002]

Acetaminophen (APAP) is a common over-the-counter medication present in more than 300 preparations for pain relief and flu-like symptoms. But for people who are suffering from viral hepatitis A or B, use of acetaminophen may play a role in accelerating liver failure, ordinarily a rare complication of viral hepatitis.

Serum samples from 72 patients with proven hepatitis A or B that had progressed to liver failure were tested for APAP adducts, which are the toxic byproducts of acetaminophen liver damage, created when a chemical (in this case, acetaminophen) binds to proteins in the liver that are then released into the blood when cells die. As a positive control group, the team also included 10 documented cases of acute liver failure (ALF) resulting directly from large APAP overdoses.

Results from the examination showed that nine of the 72 patients (12.5 percent) had detectable APAP adducts in their blood, signifying that some of their liver damage was APAP-related. All 10 known APAP-induced ALF cases had positive adducts at much higher levels than those in the viral hepatitis group (average level of 5.58 nmol/mL versus 0.45 nmol/mL, respectively). Two-thirds (67 percent) of the hepatitis patients with APAP adducts died within three weeks of study admission, compared to only 27 percent of hepatitis patients without adducts.

Most of the patients with adducts reported some APAP use in the days prior to the study, but none reported doses exceeding four grams per day. Flu-like symptoms,
'"/>

Source:American Gastroenterological Association


Page: 1 2 3 4 5 6

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel therapy combinations gain ground treating hepatitis

(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... SALT LAKE CITYResearchers have discovered two enzymes that, when ... cancer. Manipulating these enzymes genetically might lead to targeted ... tumors. "We could conceivably reactivate a completely normal ... could prevent the growth of a tumor if reactivated," ...
... crimefighter who protected the innocent from pirates, hijackers and ... its costumed namesake, this electromagnetic phantoma carbon and polymer ... the National Institute of Standards and Technology (NIST) for ... The NIST phantom serves as a mannequin in a ...
... Researchers at The University of Texas School of Public Health ... of community-acquired antibiotic-resistant Staph ylococcus aureus ... (PVL). The Panton Valentine leukocidin is made ... is typically produced by community-acquired methicillin-resistant S. aureus ...
Cached Biology News:Newly found enzymes may play early role in cancer 2Electromagnetic phantom exorcises specters of metal detector tests 2UT Public Health researchers find link to severe Staph infections 2
(Date:6/1/2015)... BAY HEAD, N.J. , June 1, 2015 /PRNewswire/ ... to launch a national innovative science curriculum for high ... announcement at the 16 th annual LIFE Event ... held at Mountain Ridge Country Club in ... some of the LPGA,s biggest stars raised more than ...
(Date:6/1/2015)... N.C. , June 1, 2015  Fennec ... presentation of positive interim results from a poster ... multi-centre open label randomised phase III trial of ... ototoxicity in patients receiving cisplatin (Cis) monotherapy for ... at the American Society of Clinical Oncology (ASCO) ...
(Date:6/1/2015)... and SOUTH SAN FRANCISCO, Calif. ... the venture arm of Baxter International Inc. (NYSE: ... LLC ("VPD") today announced the formation of Vitesse Biologics, ... by Baxter Ventures to focus on the development of ... hematology, and oncology. Following the spin-off of Baxter BioScience ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
Breaking Biology Technology:Val Skinner Foundation Announces Partnership With Discovery Education 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... Platypus Technologies of suburban Madison has received ... for $200,000 from the National Cancer Institute. The grant ... rapid quantification of protein activity, useful for cancer research. ... II SBIR grant for $2.14 million from the National ...
... been calls to run government institutions as a business, ... their shareholders: taxpayers. Now schools are facing similar scrutiny. ... Behind Act have expanded the federal regulations with which ... are also demanding more budget accountability at a time ...
... Inc ., a provider information management systems and services ... a definitive agreement to acquire BillMatrix Corp ., ... , ,BillMatrix, founded in 1994, provides billers with an ... immediate credit for bills paid online or over the ...
Cached Biology Technology:Looking to software to manage the business of education 2Looking to software to manage the business of education 3Looking to software to manage the business of education 4
... 2500ml narrow mouth PYREX low form culture flask is ... to volume ratio. This flask has a heavy beaded ... marking spot. The neck O.D. is 38mm and takes ... use this flask on a heat source smaller than ...
... The loxP-amp-loxP cassette is ... cells. The prokaryotic promoter gb2 driving ... slightly modified version of the Em7 promoter. ... generally used Tn5 promoter. A synthetic polyadenylation ...
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
... for the fast and simple integration of ... position (for the generation of transgenic mouse ... to allow neomycin / kanamycin selection in ... prokaryotic promoter (gb2) for expression of kanamycin ...
Biology Products: